Haoma Medica to Present Scientific Data on NaQuinate, a Potential New Treatment for Osteoporosis, at the Upcoming ASBMR 2020 Annual Meeting

Haoma Medica to Present Scientific Data on NaQuinate, a Potential New Treatment for Osteoporosis, at the Upcoming ASBMR 2020 Annual Meeting London, UK, 10 September 2020 - Haoma Medica announced today that it will present three scientific posters on NaQuinate at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting, which this year takes place as a virtual event from 11-15 September. NaQuinate, a naphthoquinone carboxylic acid, is being developed as a novel orally administered therapeutic for osteoporosis. ‘’Haoma Medica is dedicated to investigating new ways to treat osteoporosis and maintain healthy aging and we look forward to sharing new pre-clinical data for NaQuinate at this key meeting with bone health experts’’ said Prof Stephen Hodges, Haoma Medica’s Chief Scientific Officer more... Release: https://www.prnewswire.com/news-releases/haoma-medica-to-present-scientific-data-on-naquinate-a-potential-new-treatment-for-osteoporosis-at- asbmr-2020-annual-meeting-301127252.html?tc=eml_cleartime W hether you are a potential investor, a medical professional, a researcher, or a member of the press, we welcome enquiries and are happy to provide further information about our science, pipeline or investment opportunity. Contact Information [email protected] (CFO) [email protected] (CSO) [email protected] (CMO) Haoma Medica Ltd. c/o London BioScience Innovation Centre 2 Royal College Street London, England United Kingdom NW1 0NH LinkedIn Haoma Medica Company Registration GB No. 06784000 bottom of page

The release as fetched from its publisher. haomamedica.com ↗